|
1
|
Liu C, Xu X and Zhou Y: Association
between EGFR polymorphisms and the risk of lung cancer. Int J Clin
Exp Pathol. 8:15245–15249. 2015.PubMed/NCBI
|
|
2
|
Narod S: Can advanced-stage ovarian cancer
be cured? Nat Rev Clin Oncol. Jan 20–2016.(Epub ahead of print).
View Article : Google Scholar
|
|
3
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC CancerBase No. 11 [Internet]International Agency
for Research on Cancer; Lyon, France: 2013, http://globocan.iarc.frAccessed May 9, 2016.
|
|
4
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Macedo-Pérez EO, MoralesOyarvide V,
Mendoza-García VO, Dorantes-Gallareta Y, Flores-Estrada D and
Arrieta O: Long progression-free survival with first-line
paclitaxel plus platinum is associated with improved response and
progression-free survival with second-line docetaxel in advanced
non-small-cell lung cancer. Cancer Chemother Pharmacol. 74:681–690.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fikrova P, Stetina R, Hrnciarik M,
Hrnciarikova D, Hronek M and Zadak Z: DNA crosslinks, DNA damage
and repair in peripheral blood lymphocytes of non-small cell lung
cancer patients treated with platinum derivatives. Oncol Rep.
31:391–396. 2014.PubMed/NCBI
|
|
8
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Raymond E, Faivre S, Chaney S, Woynarowski
J and Cvitkovic E: Cellular and molecular pharmacology of
oxaliplatin. Mol Cancer Ther. 1:227–235. 2002.PubMed/NCBI
|
|
10
|
Montagnani F, Turrisi G, Marinozzi C,
Aliberti C and Fiorentini G: Effectiveness and safety of
oxaliplatin compared to cisplatin for advanced, unresectable
gastric cancer: A systematic review and meta-analysis. Gastric
Cancer. 14:50–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lowery WJ, Lowery AW, Barnett JC,
LopezAcevedo M, Lee PS, Secord AA and Havrilesky L:
Cost-effectiveness of early palliative care intervention in
recurrent platinum-resistant ovarian cancer. Gynecol Oncol.
130:426–430. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smoter M, Bodnar L, Grala B, Stec R,
Zieniuk K, Kozlowski W and Szczylik C: Tau protein as a potential
predictive marker in epithelial ovarian cancer patients treated
with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer
Res. 32:252013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao H, Bi T, Qu Z, Jiang J, Cui S and
Wang Y: Expression of miR-224-5p is associated with the original
cisplatin resistance of ovarian papillary serous carcinoma. Oncol
Rep. 32:1003–1012. 2014.PubMed/NCBI
|
|
14
|
Kuhlmann JD, Wimberger P, Bankfalvi A,
Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F,
Kimmig R and Kasimir-Bauer S: ERCC1-positive circulating tumor
cells in the blood of ovarian cancer patients as a predictive
biomarker for platinum resistance. Clin Chem. 60:1282–1289. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu Y, Fan S, Xiong Y, Peng B, Zheng G, Yu
Y, Ouyang Y and He Z: Cloning and functional characterization of
TCRP1, a novel gene mediating resistance to cisplatin in an oral
squamous cell carcinoma cell line. FEBS Lett. 585:881–887. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peng B, Gu Y, Xiong Y, Zheng G and He Z:
Microarray-assisted pathway analysis identifies MT1X & NFκB as
mediators of TCRP1-associated resistance to cisplatin in oral
squamous cell carcinoma. PLoS One. 7:e514132012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng B, Yi S, Gu Y, Zheng G and He Z:
Purification and biochemical characterization of a novel
protein-tongue cancer chemotherapy resistance-associated protein1
(TCRP1). Protein Expr Purif. 82:360–367. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu Y, Fan S, Liu B, Zheng G, Yu Y, Ouyang
Y and He Z: TCRP1 promotes radioresistance of oral squamous cell
carcinoma cells via Akt signal pathway. Mol Cell Biochem.
357:107–113. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Wang C, Gu Y, Zhang Z, Zheng G and
He Z: TCRP1 contributes to cisplatin resistance by preventing Pol β
degradation in lung cancer cells. Mol Cell Biochem. 398:175–183.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng G, Zhou M, Ou X, Peng B, Yu Y, Kong
F, Ouyang Y and He Z: Identification of carbonic anhydrase 9 as a
contributor to pingyangmycin-induced drug resistance in human
tongue cancer cells. FEBS J. 277:4506–4518. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Voland C, Bord A, Péleraux A, Pénarier G,
Carrière D, Galiègue S, Cvitkovic E, Jbilo O and Casellas P:
Repression of cell cycle-related proteins by oxaliplatin but not
cisplatin in human colon cancer cells. Mol Cancer Ther.
5:2149–2157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jobin C and Sartor RB: The IκB/NF-κB
system: A key determinant of mucosal inflammation and protection.
Am J Physiol Cell Physiol. 278:C451–C462. 2000.PubMed/NCBI
|
|
23
|
Yamano Y, Uzawa K, Saito K, Nakashima D,
Kasamatsu A, Koike H, Kouzu Y, Shinozuka K, Nakatani K, Negoro K,
et al: Identification of cisplatin-resistance related genes in head
and neck squamous cell carcinoma. Int J Cancer. 126:437–449. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dhar R and Basu A: Constitutive activation
of p70 S6 kinase is associated with intrinsic resistance to
cisplatin. Int J Oncol. 32:1133–1137. 2008.PubMed/NCBI
|
|
25
|
Lee SH, Noh KB, Lee JS, Lee EJ, Min KH,
Hur GY, Lee SH, Lee SY, Kim JH, Lee SY, et al: Thymidylate synthase
and ERCC1 as predictive markers in patients with pulmonary
adenocarcinoma treated with pemetrexed and cisplatin. Lung Cancer.
81:102–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Steffensen KD, Waldstrøm M and Jakobsen A:
The relationship of platinum resistance and ERCC1 protein
expression in epithelial ovarian cancer. Int J Gynecol Cancer.
19:820–825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Florea AM and Büsselberg D: Cisplatin as
an anti-tumor drug: Cellular mechanisms of activity, drug
resistance and induced side effects. Cancers (Basel). 3:1351–1371.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Haslehurst AM, Koti M, Dharsee M, Nuin P,
Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al: EMT
transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao H, Zhu K, Qiu L, Li S, Niu H, Hao M,
Yang S, Zhao Z, Lai Y, Anderson JL, et al: Critical role of AKT
protein in myeloma-induced osteoclast formation and osteolysis. J
Biol Chem. 288:30399–30410. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stronach EA, Chen M, Maginn EN, Agarwal R,
Mills GB, Wasan H and Gabra H: DNA-PK mediates AKT activation and
apoptosis inhibition in clinically acquired platinum resistance.
Neoplasia. 13:1069–1080. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oh H and Ghosh S: NF-κB: Roles and
regulation in different CD4(+) T-cell subsets. Immunol Rev.
252:41–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arlt A, Gehrz A, Müerköster S, Vorndamm J,
Kruse ML, Fölsch UR and Schäfer H: Role of NF-κB and Akt/PI3K in
the resistance of pancreatic carcinoma cell lines against
gemcitabine-induced cell death. Oncogene. 22:3243–3251. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bentires-Alj M, Barbu V, Fillet M, Chariot
A, Relic B, Jacobs N, Gielen J, Merville MP and Bours V: NF-κB
transcription factor induces drug resistance through MDR1
expression in cancer cells. Oncogene. 22:90–97. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pham CG, Bubici C, Zazzeroni F, Knabb JR,
Papa S, Kuntzen C and Franzoso G: Upregulation of Twist-1 by NF-κB
blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell
Biol. 27:3920–3935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun H, Wu Y, Fu D, Liu Y and Huang C:
SIRT6 regulates osteogenic differentiation of rat bone marrow
mesenchymal stem cells partially via suppressing the nuclear
factor-κB signaling pathway. Stem Cells. 32:1943–1955. 2014.
View Article : Google Scholar : PubMed/NCBI
|
